Oppenheimer Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $446K | Sell |
17,623
-1,995
| -10% | -$43.9K | ﹤0.01% | 905 |
|
|
2026
Q1 | $437K | Buy |
+19,618
| New | +$469K | 0.01% | 895 |
|
|
2025
Q4 | – | Sell |
-21,843
| Closed | -$466K | – | 1069 |
|
|
2025
Q3 | $466K | Sell |
21,843
-11,856
| -35% | -$280K | 0.01% | 917 |
|
|
2025
Q2 | $727K | Sell |
33,699
-2,165
| -6% | -$40.2K | 0.01% | 808 |
|
|
2025
Q1 | $596K | Buy |
35,864
+3,535
| +11% | +$64.2K | 0.01% | 810 |
|
|
2024
Q4 | $593K | Sell |
32,329
-5,100
| -14% | -$82.3K | 0.01% | 827 |
|
|
2024
Q3 | $576K | Buy |
37,429
+7,872
| +27% | +$131K | 0.01% | 845 |
|
|
2024
Q2 | $480K | Buy |
29,557
+2,842
| +11% | +$45.9K | 0.01% | 868 |
|
|
2024
Q1 | $494K | Sell |
26,715
-7,367
| -22% | -$183K | 0.01% | 840 |
|
|
2023
Q4 | $1.07M | Sell |
34,082
-2,111
| -6% | -$50.4K | 0.01% | 691 |
|
|
2023
Q3 | $754K | Buy |
36,193
+10,789
| +42% | +$293K | 0.01% | 754 |
|
|
2023
Q2 | $608K | Buy |
25,404
+8,502
| +50% | +$189K | 0.01% | 812 |
|
|
2023
Q1 | $318K | Buy |
16,902
+3,378
| +25% | +$64.3K | ﹤0.01% | 953 |
|
|
2022
Q4 | $215K | Sell |
13,524
-211
| -2% | -$3.3K | ﹤0.01% | 1055 |
|
|
2022
Q3 | $225K | Sell |
13,735
-862
| -6% | -$14K | ﹤0.01% | 1022 |
|
|
2022
Q2 | $206K | Sell |
14,597
-4,240
| -23% | -$79.1K | ﹤0.01% | 1074 |
|
|
2022
Q1 | $456K | Buy |
18,837
+1,478
| +9% | +$35.8K | 0.01% | 936 |
|
|
2021
Q4 | $405K | Sell |
17,359
-4,779
| -22% | -$96.1K | 0.01% | 1015 |
|
|
2021
Q3 | $368K | Sell |
22,138
-6,559
| -23% | -$126K | 0.01% | 1004 |
|
|
2021
Q2 | $700K | Sell |
28,697
-84
| -0.3% | -$1.9K | 0.01% | 857 |
|
|
2021
Q1 | $743K | Buy |
28,781
+3,999
| +16% | +$176K | 0.01% | 814 |
|
|
2020
Q4 | $1.32M | Buy |
24,782
+3,631
| +17% | +$180K | 0.02% | 598 |
|
|
2020
Q3 | $872K | Buy |
21,151
+9,175
| +77% | +$396K | 0.02% | 663 |
|
|
2020
Q2 | $580K | Buy |
11,976
+4,195
| +54% | +$201K | 0.01% | 757 |
|
|
2020
Q1 | $329K | Buy |
7,781
+1,746
| +29% | +$71.9K | 0.01% | 843 |
|
|
2019
Q4 | $258K | Buy |
6,035
+762
| +14% | +$33.1K | 0.01% | 992 |
|
|
2019
Q3 | $190K | Buy |
5,273
+1,155
| +28% | +$35K | ﹤0.01% | 1044 |
|
|
2019
Q2 | $110K | Sell |
4,118
-1,811
| -31% | -$46.3K | ﹤0.01% | 1201 |
|
|
2019
Q1 | $159K | Buy |
5,929
+17
| +0.3% | +$397 | ﹤0.01% | 1090 |
|
|
2018
Q4 | $96K | Buy |
+5,912
| New | +$115K | ﹤0.01% | 1197 |
|
|
2017
Q4 | – | Sell |
-842
| Closed | -$32K | – | 1100 |
|
|
2017
Q3 | $32K | Sell |
842
-4,291
| -84% | -$140K | ﹤0.01% | 1445 |
|
|
2017
Q2 | $143K | Buy |
5,133
+468
| +10% | +$13.9K | ﹤0.01% | 1109 |
|
|
2017
Q1 | $161K | Buy |
+4,665
| New | +$165K | ﹤0.01% | 1085 |
|
Other funds holding ACAD
BBA
RI
PAI
Oppenheimer Asset Management's ACAD Position: Q2 2026 in Review
Oppenheimer Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 10% in Q2 2026, selling an estimated $43.9K and leaving 17,623 shares worth $446K. The position accounts for ﹤0.01% of the portfolio, ranked #905.
Oppenheimer Asset Management first reported a position in ACAD in Q1 2017 and has held it in 33 quarters since. The position peaked at $1.32M in Q4 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- Oppenheimer Asset Management held 17,623 shares of Acadia Pharmaceuticals worth $446K as of Q2 2026.
- Oppenheimer Asset Management sold 1,995 Acadia Pharmaceuticals shares in Q2 2026, an estimated $43.9K.
- Acadia Pharmaceuticals made up ﹤0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #905 holding.
- Oppenheimer Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2017 and has held it in 33 quarters since.
- Oppenheimer Asset Management's Acadia Pharmaceuticals position peaked at $1.32M in Q4 2020.
- 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.